Main container

Studio di Fase 2 randomizzato in aperto, che valuta Abemaciclib in combinazione con Irinotecan e Temozolomide, in partecipanti con sarcoma di Ewing recidivato o refrattario

Title
Studio di Fase 2 randomizzato in aperto, che valuta Abemaciclib in combinazione con Irinotecan e Temozolomide, in partecipanti con sarcoma di Ewing recidivato o refrattario
Code
J1S-MC-JP04
Type
Sperimentale
Start Year
2023
Status
In Corso

Principal Investigator

Operational unit that carry out the study

Description

Lo studio è promosso da Eli Lilly and Company.

Documents and Videos attachament

Attachment
19018.pdf
Nulla osta alla conduzione dello studio clinico prot. J1S-MC-JP04
19018.pdf

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more
Content updated
03/01/2023 16:46